Dose-finding study of Topotecan (T) plus Carboplatin (C) for patients with platinum sensitive Relapsed Ovarian Cancer (ROC)

Aims: Despite effectiveness of radical surgery and first-line chemotherapy, most patients (pts) with advanced ovarian cancer will relapse. Paclitaxel (P) in combination with C as second-line treatment improves the outcome of pts with platinum-sensitive ROC in comparison to C monotherapy. Due to polyneuropathy and alopecia this regimen can not be offered to all pts. We conducted a phase I/II study to define the dose limiting toxicities (DLT) and the tolerability of T and C. Methods: Pts with platinum-sensitive ROC and primary standard therapy were stratified according to treatment-free interval (TFI): 6–12 months…